Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004;6(6):R689-96.
doi: 10.1186/bcr937. Epub 2004 Oct 11.

Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour

Affiliations

Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour

Romano Demicheli et al. Breast Cancer Res. 2004.

Abstract

Introduction: Information on the metastasis process in breast cancer patients undergoing primary tumour removal may be extracted from an analysis of the timing of clinical recurrence.

Methods: The hazard rate for local-regional and/or distant recurrence as the first event during the first 4 years after surgery was studied in 1173 patients undergoing mastectomy alone as primary treatment for operable breast cancer. Subset analyses were performed according to tumour size, axillary nodal status and menopausal status.

Results: A sharp two-peaked hazard function was observed for node-positive pre-menopausal patients, whereas results from node-positive post-menopausal women always displayed a single broad peak. The first narrow peak among pre-menopausal women showed a very steep rise to a maximum about 8-10 months after mastectomy. The second peak was considerably broader, reaching its maximum at 28-30 months. Post-menopausal patients displayed a wide, nearly symmetrical peak with maximum risk at about 18-20 months. Peaks displayed increasing height with increasing axillary lymph node involvement. No multi-peaked pattern was evident for either pre-menopausal or post-menopausal node-negative patients; however, this finding should be considered cautiously because of the limited number of events. Tumour size influenced recurrence risk but not its timing. Findings resulting from the different subsets of patients were remarkably coherent and each observed peak maintained the same position on the time axis in all analysed subsets.

Conclusions: The risk of early recurrence for node positive patients is dependent on menopausal status. The amount of axillary nodal involvement and the tumour size modulate the risk value at any given time. For pre-menopausal node-positive patients, the abrupt increase of the first narrow peak of the recurrence risk suggests a triggering event that synchronises early risk. We suggest that this event is the surgical removal of the primary tumour. The later, broader, more symmetrical risk peaks indicate that some features of the corresponding metastatic development may present stochastic traits. A metastasis development model incorporating tumour dormancy in specific micro-metastatic phases, stochastic transitions between them and sudden acceleration of the metastatic process by surgery can explain these risk dynamics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hazard rate for breast cancer recurrence (local-regional plus distant) after mastectomy alone as primary treatment in 1173 patients. Calculated values (squares) with standard deviations (oblongs) and interpolation curve covering 10 years of follow-up (a) and magnification of the first 4 years (b).
Figure 2
Figure 2
Hazard rate for breast cancer recurrence (local-regional plus distant) after mastectomy alone as primary treatment in 1173 patients: (a) pre-menopausal patients; (b) post-menopausal patients. Calculated values (squares) with standard deviations (oblongs) and interpolation curve covering the first 4 years of follow-up.
Figure 3
Figure 3
Hazard rate for breast cancer recurrence (local-regional plus distant) after mastectomy alone as primary treatment in pre-menopausal patients: (a) node-negative versus node-positive; (b) node-positive (one to three) lymph nodes; (c) node-positive (more than three) lymph nodes. Calculated values (squares and diamonds) with standard deviations (oblongs) and interpolation curve covering the first 4 years of follow-up (N-, 34 events; N+(1–3), 61 events; N+(>3), 60 events).
Figure 4
Figure 4
Hazard rate for breast cancer recurrence (local-regional plus distant) after mastectomy alone as primary treatment in post-menopausal patients: (a) node-negative versus node-positive; (b) node-positive (one to three) lymph nodes; (c), node-positive (more than three) lymph nodes. Calculated values (squares and diamonds) with standard deviations (oblongs) and interpolation curve covering the first 4 years of follow-up (N-, 40 events; N+(1-3), 84 events; N+(>3), 88 events).

Comment in

References

    1. Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelem M, Band P, Katrych DL, et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med. 1975;292:117–122. - PubMed
    1. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, DeLena M, Tancini G, Bajetta E, Musumeci R, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405–410. - PubMed
    1. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of randomized trials. Lancet. 1998;351:1451–1467. doi: 10.1016/S0140-6736(97)11423-4. - DOI - PubMed
    1. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer: an overview of randomized trials. Lancet. 1998;352:930–942. doi: 10.1016/S0140-6736(98)03301-7. - DOI - PubMed
    1. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N Engl J Med. 1995;332:901–906. doi: 10.1056/NEJM199504063321401. - DOI - PubMed